Company Overview and News

 
Jameson Resources heads to market for coking coal

2017-09-16 proactiveinvestors.com.au
Jameson Resources Ltd (ASX:JAL) has been granted a trading halt by the ASX this morning, pending details of a capital raising.

 
Jameson Resources to lift cash balance for coking coal interests

2017-05-30 proactiveinvestors.com.au
Jameson Resources (ASX:JAL) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Jameson Resources making progress on Canadian coal project

2016-12-19 proactiveinvestors.com.au
The project is located in the Elk Valley coal field and adjacent to the Crows Nest coal field. Together, these coal fields are home to five of Canada's 23 producing coal mines. These mines produce over 21 million tonnes per annum of export quality metallurgical and thermal coal, which is more than 70% of Canada's annual total coal exports. Jameson had applied for this license in 2013. The area covered by the application has been moderately reduced (by less than 5%) to eliminate an overlap with adjacent private lands.

 
Jameson Resources Ltd raise cash as shares continue to trade higher

2016-10-07 proactiveinvestors.com.au
Jameson Resources Ltd (ASX:JAL) has completed a share placement to raise $1 million to continue advancing the 90% owned Crown Mountain coking coal project in Canada. Shares in the company traded up 50% intra-day continuing their strong year to date, up 200%. 14.3 million shares will be issued at $0.07, representing a 40% premium to the last traded price pre-placement. Funds will be used to update the Crown Mountain pre-feasibility study, continue the environmental assessment process, perform a gap analysis on Crown Mountain baseline data, and for general corporate purposes.

 
Jameson Resources Ltd raise cash as shares continue to trade higher

2016-10-03 proactiveinvestors.com.au
Jameson Resources Ltd (ASX:JAL) has completed a share placement to raise $1 million to continue advancing the 90% owned Crown Mountain coking coal project in Canada. Shares in the company traded up 50% intra-day continuing their strong year to date, up 200%. 14.3 million shares will be issued at $0.07, representing a 40% premium to the last traded price pre-placement. Funds will be used to update the Crown Mountain pre-feasibility study, continue the environmental assessment process, perform a gap analysis on Crown Mountain baseline data, and for general corporate purposes.

 
Jameson Resources Ltd to lift cash position

2016-09-28 proactiveinvestors.com.au
Jameson Resources Ltd (ASX:JAL) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. The halt will remain in place until the opening of trade on Monday 3rd October 2016, or earlier if an announcement is made to the market.

 
 
Quarterly Activities Report

2016-04-18 asx.com.au

 
Quarterly Cashflow Report

2016-04-18 asx.com.au

 
 
Half Yearly Report and Accounts

2016-03-03 asx.com.au

 
 
 
Quarterly Activities Report

2016-01-25 asx.com.au

 
Quarterly Cashflow Report

2016-01-25 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...